Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target SCIENCE ADVANCES Tzarum, N., Giang, E., Kadam, R. U., Chen, F., Nagy, K., Augestad, E. H., Velazquez-Moctezuma, R., Keck, Z., Hua, Y., Stanfield, R. L., Dreux, M., Prentoe, J., Foung, S. H., Bukh, J., Wilson, I. A., Law, M. 2020; 6 (30): eabb5642

Abstract

To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host receptors. Many nAbs bind to the "neutralizing face" on E2, including several broadly nAbs encoded by the VH1-69 germline gene family that bind to a similar conformation (A) of this face. Here, a previously unknown conformation (B) of the neutralizing face is revealed in crystal structures of two of four additional E2-VH1-69 nAb complexes. In this conformation, the E2 front-layer region is displaced upon antibody binding, exposing residues in the back layer for direct antibody interaction. This E2 B structure may represent another conformational state in the viral entry process that is susceptible to antibody neutralization and thus provide a new target for rational vaccine development.

View details for DOI 10.1126/sciadv.abb5642

View details for Web of Science ID 000552228100039

View details for PubMedID 32754640

View details for PubMedCentralID PMC7380959